Cytokinetics

CYTK

Biotech

Health Care

Pharma

Country

US

Industry

Health Care

Market Cap

Mid Cap

Num. Employees

409

IPO Date

Apr 29, 2004

Create Alert

CYTK

Country

US

Industry

Health Care

Biotech

Health Care

+1

Create Alert

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The company is headquartered in South San Francisco, California and currently employs 409 full-time employees. The company went IPO on 2004-04-29. The firm is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The firm's clinical-stage drug candidates are: omecamtiv mecarbil, a cardiac myosin activator for the treatment of heart failure with reduced ejection fraction (HFrEF); CK-136, a cardiac troponin activator for the treatment of heart failure and other diseases; reldesemtiv , a fast skeletal muscle troponin activator (FSTA) for the treatment of people living with debilitating diseases and conditions associated with muscular weakness; aficamten, a cardiac myosin inhibitor designed to reduce the hypercontractility that is associated with hypertrophic cardiomyopathy (HCM); and CK-136 an novel small molecule cardiac troponin activator.